UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant to
Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): February 10,
2020
DARÉ
BIOSCIENCE, INC.
(Exact name of
registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-36395
|
|
20-4139823
|
|
(State or other
jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
3655 Nobel
Drive, Suite 260
San Diego, CA
92122
(Address of
Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (858) 926-7655
Not
Applicable
(Former name or
former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction
A.2. below):
|
|
|
|
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
Common
Stock
|
DARE
|
Nasdaq Capital
Market
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ¨
Included as Exhibit
99.1 to this report is a presentation about Daré and its product
candidates, dated February 10, 2020, which is incorporated herein
by reference. Daré intends to use the presentation and its contents
in various meetings with investors, securities analysts and others,
commencing on February 11, 2020.
|
|
|
|
Item 9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits.
|
|
|
|
Exhibit
No.
|
Description
|
|
99.1
|
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
DARÉ
BIOSCIENCE, INC.
|
|
Date: February 10,
2020
|
|
|
By:
|
|
/s/ Sabrina Martucci
Johnson
|
|
|
|
|
Name:
|
|
Sabrina Martucci
Johnson
|
|
|
|
|
Title:
|
|
President and Chief Executive
Officer
|
